Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 6, 2009, Pages 1089-1096

  Chiu, Yi Wen ^a,b   Teitelbaum, Isaac ^c   Misra, Madhukar ^d   De Leon, Essel Marie ^a   Adzize, Tochi ^a   Mehrotra, Rajnish ^a,e  

^a LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM ACETATE; CALCIUM CARBONATE; CARDIOVASCULAR AGENT; CINACALCET; GASTROINTESTINAL AGENT; HORMONE; LANTHANUM CARBONATE; PSYCHOTROPIC AGENT; SEVELAMER; VITAMIN D DERIVATIVE; PHOSPHORUS;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BICARBONATE BLOOD LEVEL; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DIALYSIS; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOME DIALYSIS; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; POLYPHARMACY; QUALITY OF LIFE; AGED; BLOOD; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; COMORBIDITY; COST OF ILLNESS; CROSS-SECTIONAL STUDY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTION AND FORECASTING; PREVALENCE; PSYCHOLOGICAL ASPECT; RENAL REPLACEMENT THERAPY; SENSITIVITY AND SPECIFICITY; STATISTICS;

ADULT; AGED; COHORT STUDIES; COMORBIDITY; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHORUS; PREDICTIVE VALUE OF TESTS; PREVALENCE; QUALITY OF LIFE; RENAL DIALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 69249206871     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00290109     Document Type: Article

References (23)

1. USRDS 2008 Annual Data Report. US Renal Data System, in 2008
2. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB: Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 3: 329-338, 1994
3. Evans RW, Manninen DL, Garrison LP, Jr., Hart LG, Blagg CR, Gutman RA, Hull AR, Lowrie EG: The quality of life of patients with end-stage renal disease. N Engl J Med 312: 553-559, 1985
4. Mapes DL, Lopes AA, Satayathum S, McCullough KP, Goodkin DA, Locatelli F, Fukuhara S, Young EW, Kurokawa K, Saito A, Bommer J, Wolfe RA, Held PJ, Port FK: Health-related quality of life as a predictor of mortality and hospitalization: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 64: 339-349, 2003
5. Lowrie EG, Curtin RB, LePain N, Schatell D: Medical outcomes study short form-36: A consistent and powerful predictor of morbidity and mortality in dialysis patients. Am J Kidney Dis 41: 1286-1292, 2003
6. Knight EL, Ofsthun N, Teng M, Lazarus JM, Curhan GC: The association between mental health, physical function, and hemodialysis mortality. Kidney Int 63: 1843-1851, 2003
7. Kimmel PL, Patel SS: Quality of life in patients with chronic kidney disease: Focus on end-stage renal disease treated with hemodialysis. Semin Nephrol 26: 68-79, 2006
8. Weisbord SD, Fried LF, Arnold RM, Fine MJ, Levenson DJ, Peterson RA, Switzer GE: Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol 16: 2487-2494, 2005
9. The USRDS Dialysis Morbidity and Mortality Study: Wave 2. United States Renal Data System. Am J Kidney Dis 30: S67-S85, 1997
10. Manley HJ, Garvin CG, Drayer DK, Reid GM, Bender WL, Neufeld TK, Hebbar S, Muther RS: Medication prescribing patterns in ambulatory haemodialysis patients: Comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant 19: 1842-1848, 2004
11. Kalpakian MA, Mehrotra R: Vascular calcification and disordered mineral metabolism in dialysis patients. Semin Dial 20: 139-143, 2007
12. Karamanidou C, Clatworthy J, Weinman J, Horne R: A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 9: 2, 2008
13. Ware JE, Snow KK, Kosinski M, Keller SD: SF-36 physical and mental health summary scales: A user's manual. Boston: The Health Institute, New England Medical Center, 1994
14. Vanderpoel DR, Hussein MA, Watson-Heidari T, Perry A: Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: A retrospective database analysis. Clinical Therapeutics 26: 2066-2075, 2004
15. Frishman WH: Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev 15: 257-263, 2007
16. Bartlett JA, Fath MJ, Demasi R, Hermes A, Quinn J, Mondou E, Rousseau F: An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDs 20: 2051-2064, 2006
17. Ingersoll KS, Cohen J: The impact of medication regimen factors on adherence to chronic treatment: A review of literature. J Behav Med 31: 213-224, 2008
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr., Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289: 2560-2572, 2003
19. Fischer D, Cline K, Plone MA, Dillon M, Burke SK, Blair AT: Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing. Am J Kidney Dis 48: 437-444, 2006
20. Mehrotra R, Martin KJ, Fishbane S, Sprague SM, Zeig S, Anger M: Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: A multicenter study. Clin J Am Soc Nephrol 3: 1437-1445, 2008
21. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
22. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2005
23. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB, Sr., Gaziano JM, Vasan RS: Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 167: 879-885, 2007